Persistant Atrial Fibrillation: Pulse Field Ablation Dominates

About this episode

This episode discusses a landmark trial that redefines first-line therapy in persistent atrial fibrillation, highlighting the superiority of pulsed field ablation over traditional antiarrhythmic drugs.

⚡🫀 Shock. Silence. Success — A landmark New England Journal of Medicine trial redefines first-line therapy in persistent AF. In AVANT GUARD, pulsed field ablation (PFA) outperformed antiarrhythmic drugs: 📊 Success: 56% vs 30% 📉 HR: 0.46 (P 💓 Lower arrhythmia burden (−6.5%) Safety remained comparable, with primary events at 5.1%. A compelling case for early, energy-based rhythm control —precision over pharmacology. #Cardiology #Electrophysiology #AtrialFibrillation #NEJM #Innovation

People in this episode

Host: Dr RR Baliga

Topics covered

• Atrial Fibrillation
• Cardiology
• Electrophysiology
• Medical Innovation
• Rhythm Control

Keywords

• Persistent Atrial Fibrillation
• Pulsed Field Ablation
• Antiarrhythmic Drugs
• NEJM
• Cardiology
• Rhythm Control
• Clinical Trial
• Safety
• Arrhythmia Burden

Mentioned in this episode

Organizations: New England Journal of Medicine, AVANT GUARD

More episodes of Dr RR Baliga's "Got Knowledge Doc" Podkast

• 🎯 Septic Shock, Hemodynamic Support, A Neutral Trial with Important Lessons · June 12, 2026 · 4 min
• One Syndrome, Three Systems, Infinite Consequences: The 2026 CKM Guideline for Integrated Cardiovascular–Kidney–Metabolic Care · June 11, 2026 · 8 min
• Earlier. Smarter. Stronger ⚡ — 🫀 — The 2026 ACC/AHA Dyslipidemia Playbook · June 10, 2026 · 10 min
• Great Doctors Series: Herophilus and the Birth of Scientific Anatomy ⚕️🌍 · June 9, 2026 · 3 min
• 🫀 The Heart on Fire: New Frontiers in Cardiovascular Inflammation · June 8, 2026 · 3 min
• 🫁 Predict, Prevent, Protect: Plasma Signals That Foretell Lung Cancer Years Ahead · June 7, 2026 · 4 min